Minute Insight: Pear Therapeutics Files For Bankruptcy, Hopes To Find Buyer For PDT Assets
Executive Summary
A few weeks after announcing that it was exploring its "strategic options," Pear Therapeutics announced that it is filing for bankruptcy and is not filling new prescriptions for its digital therapeutics.
You may also be interested in...
Updated: Pear Therapeutics PDTs Reborn In PursueCare, Supported By Pear's Ex-CEO
Pear Therapeutic’s PDTs have a new home at PursueCare thanks to $20m in series B funding led by Tr.X Capital, led by Pear's former CEO.
Better Therapeutics Plans Diabetes PDT Launch Following FDA De Novo Authorization
FDA authorized Better Therapeutics’ AspyreRx, formerly known as BT-001, a prescription-only digital therapeutic that provides cognitive behavioral therapy to adults with type 2 diabetes. The company plans to launch it in the fourth quarter of 2023.
The Afterlife Of Pear Therapeutics: Korean DTx Maker Discusses Vision For Salvaged Migraine Assets
WELT USA was among four companies that competed at auction for Pear assets following the digital therapeutics trailblazer’s Chapter 11 bankruptcy filing in April. WELT also bid on Pear’s reSET assets for treating substance use disorder, but was pleased that they went to Pear’s former CEO Corey McCann – “a good signal to the industry,” says WELT USA head Danny Kim.